Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03486327 · ClinicalTrials.gov registry record · Phase 2
Transabdominal Ultrasound With BR55 for Characterization of Pancreatic Lesions
A Phase 2 study, sponsored by Bracco Diagnostics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT03486327 is a Phase 2 study that was terminated before completion, run by Bracco Diagnostics. The registered enrollment target is 4 participants.
The verdict
NCT03486327, a Phase 2 study, was terminated before completion, sponsored by Bracco Diagnostics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
This is an exploratory, single center, open label, parallel-dose, and prospective study of BR55 contrast-enhanced ultrasonography (CEUS) for characterization of solid pancreatic lesions in subjects with suspected pancreatic ductal adenocarcinoma (PDAC) using transabdominal US.
Interventions
- DRUG BR55
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2018-07-19 |
| Est. Completion | 2021-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03486327
The ClinicalTrials.gov registry entry for NCT03486327 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bracco Diagnostics, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BR55 is the first listed.
NCT03486327 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03486327 about?
NCT03486327 is a clinical study titled "Transabdominal Ultrasound With BR55 for Characterization of Pancreatic Lesions". This is an exploratory, single center, open label, parallel-dose, and prospective study of BR55 contrast-enhanced ultrasonography (CEUS) for characterization of solid pancreatic lesions in subjects with suspected pancreatic ductal adenocarcinoma (PDAC) using transabdominal US.
What is the current status of trial NCT03486327?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2018-07-19. Estimated completion is 2021-07-31.
What interventions are being tested in trial NCT03486327?
The interventions under investigation include: BR55 (DRUG).
Who is sponsoring clinical trial NCT03486327?
This trial is sponsored by Bracco Diagnostics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.